Malaria parasite CelTOS targets the inner leaflet of cell membranes for pore-dependent disruption

John R. Jimah
Washington University School of Medicine in St. Louis

Nichole D. Salinas
Washington University School of Medicine in St. Louis

Monica Sala-Rabanal
Washington University School of Medicine in St. Louis

Nathaniel G. Jones
Washington University School of Medicine in St. Louis

L. David Sibley
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Jimah, John R.; Salinas, Nichole D.; Sala-Rabanal, Monica; Jones, Nathaniel G.; Sibley, L. David; Nichols, Colin G.; Schlesinger, Paul H.; and Tolia, Niraj H., "Malaria parasite CelTOS targets the inner leaflet of cell membranes for pore-dependent disruption." Elife. 5,. e20621. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/6327

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Malaria parasite CelTOS targets the inner leaflet of cell membranes for pore-dependent disruption

John R Jimah1, Nichole D Salinas1, Monica Sala-Rabanal2,3, Nathaniel G Jones1, L David Sibley1, Colin G Nichols2,3, Paul H Schlesinger2, Niraj H Tolia1,4

1Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, United States; 2Department of Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, United States; 3Center for the Investigation of Membrane Excitability Diseases, Washington University School of Medicine, Saint Louis, United States; 4Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, United States

Abstract Apicomplexan parasites contain a conserved protein CelTOS that, in malaria parasites, is essential for traversal of cells within the mammalian host and arthropod vector. However, the molecular role of CelTOS is unknown because it lacks sequence similarity to proteins of known function. Here, we determined the crystal structure of CelTOS and discovered CelTOS resembles proteins that bind to and disrupt membranes. In contrast to known membrane disruptors, CelTOS has a distinct architecture, specifically binds phosphatidic acid commonly present within the inner leaflet of plasma membranes, and potently disrupts liposomes composed of phosphatidic acid by forming pores. Microinjection of CelTOS into cells resulted in observable membrane damage. Therefore, CelTOS is unique as it achieves nearly universal inner leaflet cellular activity to enable the exit of parasites from cells during traversal. By providing novel molecular insight into cell traversal by apicomplexan parasites, our work facilitates the design of therapeutics against global pathogens.

DOI: 10.7554/eLife.20621

Introduction

Apicomplexan parasites of the genera Plasmodium, Babesia, Cyttauxzoon and Theileria are responsible for the established and emerging global infectious diseases malaria (Black et al., 2010; Price et al., 2007), babesiosis (Homer et al., 2000), cytauxzoonosis (Sherrill et al., 2015), and theileriosis (Shaw, 2003), respectively. Although these parasites infect a range of hosts and cause different diseases, they share biological adaptations for traversal through a variety of cells within their mammalian hosts and arthropod vectors to complete their life cycle (Homer et al., 2000; Sherrill et al., 2015; Shaw, 2003; Mota et al., 2001; Yuda and Ishino, 2004; Amino et al., 2008; Sinnis and Zavala, 2012; Ménard et al., 2013; Gueirard et al., 2010).Traversal refers to the ability of a eukaryotic parasite to move through host or vector cells to complete essential segments of a complicated life cycle. Within the host, cell traversal by parasites is essential for successful infection as sporozoites must negotiate and cross several distinct cell types until they enter defined cells that are receptive for replication, leading to disease progression. Traversal is also essential for transmission by vectors as parasites must cross the arthropod midgut epithelia to mature into sporozoites that are the transmissible form of these apicomplexan parasites.

Traversal of parasites through host and vector cells relies on a number of different biological processes mediated by various parasite proteins. Gliding motility is the characteristic motion of
parasites as they move through various tissues and invade cells (Yuda and Ishino, 2004; Ménard et al., 2013; Harupa et al., 2014; Moreira et al., 2008). Parasites also physically breach cell barriers during the invasion of cells (Homer et al., 2000; Sherrill et al., 2015; Shaw, 2003; Mota et al., 2001; Yuda and Ishino, 2004; Amino et al., 2008; Kadota et al., 2004; Risco-Castillo et al., 2015). Finally, parasites have developed strategies for immune evasion as they migrate through various cells, including phagocytic Kupffer cells (Sinnis and Zavala, 2012; Zheng et al., 2014). Ongoing efforts to identify and elucidate the function and mechanism of parasite proteins involved in diverse cell traversal processes will advance our understanding of parasite biology, and will unveil new targets for therapeutics. Of all the apicomplexan parasites, therapeutics for Plasmodium falciparum and Plasmodium vivax are desperately needed as these parasites are leading causes of human death and major burdens to socio-economic development (Black et al., 2010; Price et al., 2007).

Cell-traversal protein for ookinetes and sporozoites (CelTOS) is unique among traversal proteins as it is essential for traversal of malaria parasites in both the mosquito vector and human host and is therefore critical for malaria transmission and disease pathogenesis (Kariu et al., 2006). Additionally, CelTOS has been identified as a promising malaria vaccine candidate referred to as Antigen 2 (Doolan et al., 2003). Immunization of mice with recombinant CelTOS results in humoral and cellular immune responses that reduced infection, demonstrating that targeting CelTOS is a viable approach for developing a malaria vaccine (Bergmann-Leitner et al., 2010; Ferraro et al., 2013; Bergmann-Leitner et al., 2011, 2013). Even though CelTOS is critical during cell traversal by malaria parasites and is a leading transmission- and infection-blocking malaria vaccine candidate, its function remains unknown as it has no sequence similarity to proteins of known function.

Jimah et al. eLife 2016;5:e20621. DOI: 10.7554/eLife.20621
In this study, we determined the structure of CelTOS in order to gain insight into its function. CelTOS structurally resembles viral membrane fusion proteins and a bacterial pore-forming toxin. This observation informed our hypothesis that apicomplexan CelTOS directly binds to and breaches plasma membranes. We show that CelTOS specifically binds phosphatidic acid, a lipid predominantly found in the inner leaflet of plasma membranes, and potently disrupts defined liposomes composed of phosphatidic acid. We determine that liposome disruption is achieved by the formation of CelTOS-dependent pores. Additionally, microinjection of CelTOS into Xenopus oocytes results in membrane damage. Together, these results demonstrate CelTOS is the only known apicomplexan protein with universal inner leaflet cellular activity as it addresses phosphatidic acid found specifically on the cytoplasmic face of plasma membranes, and disrupts these membranes to enable the exit of apicomplexan parasites through diverse vector and host cells. In addition to discovering this unique role of CelTOS in cell traversal, our work on the structure, function, and mechanism of CelTOS will enable structural vaccinology (Dormitzer et al., 2012) to produce a potent protective malaria vaccine, and inform the development of other therapeutics targeting CelTOS.

Results

CelTOS is conserved in apicomplexans

As CelTOS is important for multiple stages of the parasite life cycle, we examined if CelTOS was evolutionarily conserved among other apicomplexan pathogens, including those with recently sequenced genomes. We found CelTOS is conserved across various diverse branches of apicomplexan parasites including the hemosporidia (Plasmodium spp.) and piroplasms (Theileria, Babesia, Cytauxzoon spp.), groups that are thought to have diverged more than 100 million years ago (DeBarry and Kissinger, 2011) (Figure 1A and Figure 1—figure supplement 1). Hence, CelTOS represents an ancient and widespread adaptation that is common to apicomplexans that have two host life cycles alternating between asexual replication in their vertebrate hosts and a sexual cycle in their arthropod vectors. This is supported by the lack of CelTOS in the apicomplexan Toxoplasma gondii that does not require an arthropod vector for transmission. This evolutionary conservation and importance in disease pathogenesis and transmission prompted the in-depth molecular study of CelTOS that is applicable to diverse pathogenic apicomplexan parasites.

Structure of Plasmodium CelTOS

The mechanism by which CelTOS enables the traversal of apicomplexan parasites through cells within the mammalian host and arthropod vector has been elusive because CelTOS has no sequence similarity to proteins of known function. Therefore, we determined the crystal structure of CelTOS from the human pathogen P. vivax (PvCelTOS) in order to obtain insight into function (Figure 1, Figure 1—figure supplement 2 and Figure 1—source data 1). As CelTOS is highly conserved across apicomplexans (Figure 1A and Figure 1—figure supplement 1), the structural inferences derived from the PvCelTOS structure will apply to apicomplexan parasites generally. CelTOS forms an alpha helical dimer that resembles a tuning fork (Figure 1B). The dimer has a large buried surface area of 3003 Å². Consistent with the structure and large buried surface area, we established that CelTOS is an obligate dimer in solution by sedimentation equilibrium analytical ultracentrifugation (Figure 1—source data 2). Two N-terminal helices (α-helices 1 and 2) of one monomer pack against the C-terminal helices (α-helices 3 and 4) of a second monomer to form the dimer. The outer surface of the CelTOS dimer is mildly hydrophilic (Figure 1C and E) and masks inner hydrophobic surfaces created between the two tines of the CelTOS dimer and the dimer interface (Figure 1E).

CelTOS resembles proteins that disrupt membranes

We compared the structure of the CelTOS monomer (Figure 1D) against all structures in the Protein Data Bank to identify proteins with similar structure and to inform function using the DALI server (Holm et al., 2010). Strikingly, CelTOS resembles class I viral membrane fusion glycoproteins and a bacterial pore-forming toxin with roles in membrane binding and disruption (Figure 2). The C-terminal helices of CelTOS show structural similarity to HIV-1 gp41 (Figure 2A) and Mycobacterium bovis ESAT-6 (Figure 2D), and the N-terminal helices show similarity to Hendravirus fusion core (Figure 2B); Nipahvirus fusion subunit core (Figure 2C) (Buzon et al., 2010; Lou et al., 2006;
This informed the hypothesis that Plasmodium CelTOS may function to bind and disrupt cell membranes, consistent with a role in host and vector cell traversal by malaria parasites. While CelTOS resembles these viral and bacterial proteins, the CelTOS structure is unique and distinct as it contains two independent subdomains that both could act as membrane disruption modules.

CelTOS specifically binds phosphatidic acid

Given this structural similarity, we examined if CelTOS could directly bind cell membrane phospholipids and if binding was specific to a particular lipid subset using spotted arrays. Both P. falciparum (Pf) and P. vivax (Pv) CelTOS demonstrated significant binding to phosphatidic acid (PA) (Figure 3).
The specificity to this small anionic headgroup phospholipid is unique and excludes other anionic but large headgroup phospholipids. Phosphatidic acid is predominantly found on the inner leaflet of plasma membranes (Op den Kamp, 1979). Specific binding of PvCelTOS to cardiolipin was also observed. However, the relevance of this binding specificity is unclear as it is not conserved in

Figure 2. PvCelTOS is structurally similar to viral and bacterial proteins that disrupt membranes. All panels are structural overlays of PvCelTOS (green) with pathogenic membrane disrupting proteins (orange): (A) HIV-1 gp41 PDB 3P30 (Dali Z-score: 3.2, rmsd 3.2), (B) Hendravirus fusion protein PDB 3N27 (Dali Z-score: 3.1, rmsd 3.3) (orientation of CelTOS is rotated 60° along the y-axis compared to Figure 2A), (C) Nipahvirus fusion protein PDB 1WP7 (Dali Z-score: 3.3, rmsd 2.9) (orientation of CelTOS is rotated 60° along the y-axis compared to Figure 2A), and (D) Mycobacterium bovis ESAT-6 PDB 1WA8 (Dali Z-score: 2.6, rmsd 2.3).

DOI: 10.7554/eLife.20621.008

Figure 3. CelTOS binds the inner leaflet cell membrane lipid phosphatidic acid. (A) Spotted lipid array probed with PfCelTOS demonstrates significant binding to PA compared to the negative control (BB) in lipid arrays. Right panel: Normalized binding intensity from eight experiments shown as mean ± s.e.m. Statistical differences were determined by one-way ANOVA with matched replicates, followed by Dunnett’s multiple comparison test; *p<0.05, **p<0.01, ***p<0.001. GT - Glyceryl tripalmitate, DAG - Diacylglycerol, PA - Phosphatidic Acid, PS - Phosphatidylserine, PE - Phosphatidylethanolamine, PC - Phosphatidylcholine, PG - Phosphatidylglycerol, CL - Cardiolipin, PI - Phosphatidylinositol, PI4P - Phosphatidylinositol (4)-phosphate, PI4,5P2 - Phosphatidylinositol (4,5)-bisphosphate, PI(3,4,5)P3 - Phosphatidylinositol (3,4,5)-trisphosphate, CH - Cholesterol, SM - Sphingomyelin, SF - 3-sulfogalactosylceramide, and BB - Blue blank. (B) Spotted lipid array probed with PvCelTOS demonstrates significant binding to PA and PS compared to the negative control (BB) in lipid arrays. Right panel: Normalized binding intensity from three experiments shown as mean ± s.e.m. Statistical differences were determined by one-way ANOVA with matched replicates, followed by Dunnett’s multiple comparison test; *p<0.05, **p<0.01, ***p<0.001. Acronyms as in Figure 3A.

DOI: 10.7554/eLife.20621.009
CelTOS from both *P. falciparum* and *P. vivax*. Limited or undetectable binding was observed to phospholipids predominantly found on the outer leaflet of plasma membranes including sphingomyelin (SM) and phosphatidylcholine (PC) (*Op den Kamp, 1979*). These results demonstrate that CelTOS has enhanced specificity for the cytosolic face of cell membranes and suggests CelTOS possesses a specific binding pocket that preferentially accommodates PA over the headgroups of other phospholipids.

**CelTOS disrupts liposomes containing phosphatidic acid**

Further to identifying its lipid-binding specificity, we established that CelTOS disrupts membranes in a liposome disruption assay (*Figure 4 and Figure 4—figure supplement 1*) (*Saito et al., 2000*). Liposomes that mimic cell membranes were created containing carboxyfluorescein at self-quenching concentrations using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (POPA), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC). Liposomes containing 8:2 POPC:POPA mixtures (PA liposomes) or 8:2 POPC:POPS mixtures (PS liposomes) were disrupted by CelTOS.

![Figure 4.](https://example.com/figure4.png)

**Figure 4.** CelTOS disrupts liposomes containing phosphatidic acid (PA liposomes). (A) Time dependence of liposome disruption at various concentrations of PfCelTOS, a representative plot of three independent experiments is presented. The solid lines represent the fit of liposome disruption to *Equation 2* and the dashed lines represent the raw data of liposome disruption. (B) The time constant, Tau, determined from the fit to *Equation 2*, is plotted against the concentration of PfCelTOS for three technical replicates is shown as mean ± s.e.m. (C) Time dependence of liposome disruption at various concentrations of PvCelTOS. (D) The time constant, Tau, plotted against the concentration of PvCelTOS.

DOI: 10.7554/eLife.20621.010

The following figure supplement is available for figure 4:

**Figure supplement 1.** CelTOS minimally disrupts liposomes composed of phosphatidyserine and phosphatidylcholine, and the negative control protein EcIsPF does not disrupt the liposomes composed of the aforementioned lipids and phosphatidic acid.

DOI: 10.7554/eLife.20621.011
liposomes) represent the inner leaflet of plasma membranes, while pure POPC (PC liposomes) repre-
sents the outer leaflet.

Upon incubation of either Pf or PvCelTOS with PA liposomes, carboxyfluorescein was released, 
fluorescence dequenched, and the time-dependent increase in liposome disruption was measured 
(Figure 4).

Nanomolar concentrations of CelTOS disrupted PA liposomes consistent with a potent role in the 
disruption of PA containing membranes (Figure 4). In contrast, minimal disruption of PS and PC lipo-
somes by CelTOS was observed and this required micromolar concentrations of CelTOS (Figure 4—
figure supplement 1A–C). Liposome disruption was specific to CelTOS as addition of the control 
protein E. coli IspF, that has similar mass, isoelectric point and purification method as CelTOS, had 
no effect (Figure 4—figure supplement 1D). These results demonstrate that the CelTOS protein 
alone is necessary and sufficient for membrane disruption, specifically targets inner leaflet phospha-
tidic acid lipid compositions, and has a conserved function across Plasmodium spp.

**CelTOS disrupts liposomes by forming pores**

We investigated the mechanism by which CelTOS disrupts liposomes. CelTOS could disrupt lipo-
somes either by generalized solubilization and mixed micelle formation similar to detergents, or by 
forming defined protein-dependent pores within the lipid bilayer. A key test of pore formation is 
whether leakage of liposome contents can be prevented by plugging the pore using a molecule of 
the correct Stoke’s radius (Saito et al., 2000). We examined the CelTOS-dependent release of car-
boxyfluorescein from liposomes in the presence of 20 μM dextran molecules of various molecular 
weights: 66.9 kDa (Stoke’s radius:~5.8 nm), 148 kDa (Stoke’s radius:~8 nm), 500 kDa (Stoke’s radius: 
14.7 nm), 1500–2800 kDa (Stoke’s radius ranging from ~25 to ~60 nm (Tang et al., 2016); Stoke’s 
radius of 2000 kDa Dextran: 27 nm [Armstrong et al., 2004]). Remarkably, only the 500 kDa dextran 
blocked carboxyfluorescein release from liposomes disrupted with PfCelTOS and PvCelTOS, respec-
tively (Figure 5A and B). Dextran molecules of higher and lower molecular weights and Stoke’s radius 
had no effect on carboxyfluorescein release, similar to experiments without dextran. There-
fore, only the 500 kDa dextran has the correct Stoke’s radius to occupy the pore, while the remaining 
dextran molecules are either too small and diffuse through the pore or too large and may not 
enter the pore. The 500 kDa dextran significantly lowered the maximum amount of carboxyfluores-
cein released disrupted (A, in Equation 2) compared to experiments with molecules of higher and 
lower molecular weights, or without dextran (Figure 5—figure supplement 1). This suggests that 
CelTOS forms pores of uniform size in liposomes and that the dextran-pore complex might be slowly 
reversibly tying up the protein in a non-functional pore. We visualized the CelTOS-pore in liposomes 
by transmission electron microscopy of negative stained liposomes (Figure 5C). The average diame-
ter of the pores, reported as mean ± s.d., formed by PfCelTOS and PvCelTOS were 45.85 ± 15.55 
nm and 58.62 ± 21.86 nm respectively (Figure 5—figure supplement 2). The dextran-blocking and 
electron microscopy studies suggest CelTOS forms a pore that opens a portal for parasite exit from 
invaséd cells. The observed portal is large and strongly suggests that the membrane structure of 
CelTOS may continue to evolve after the initial carboxyfluorescein release.

**CelTOS disrupts cell plasma membranes by targeting the inner leaflet**

The structural and activity data above suggest CelTOS functions within the cytosol of host and vec-
tor cells to disrupt cell plasma membranes from the cytoplasmic face. To test this hypothesis, we 
microinjected purified CelTOS into the cytosol of Xenopus oocytes and examined the effects on 
membrane integrity and cell survival (Figure 6A and B, and Figure 6—figure supplement 1). Micro-
injection allows for direct examination of the cellular effect of proteins. Only minor membrane phe-
notypes due to the injection process were observed in oocytes injected with buffer and in those 
injected with the negative control protein, EclspF. In contrast, microinjection of Pf or PvCelTOS 
caused significant increase in the number of cells that had damaged membranes (Figure 6A and B, 
and Figure 6—figure supplement 1).

We examined if CelTOS can disrupt cell membranes from the extracellular face using RAW 264.7 
macrophages. The cell membrane of Xenopus oocytes is protected from the extracellular environ-
ment by a vitelline membrane. This makes oocytes unsuitable for studying the effect of CelTOS on 
the outer surface of cell membranes. RAW macrophages have an exposed cell membrane and are
an especially relevant model as they are similar to liver macrophages (Kupffer cells), which are traversed by malaria parasites in a CelTOS-dependent process. No membrane disruption, measured by uptake of a membrane-impermeable fluorescent dye, was observed for macrophages in tissue culture when CelTOS was added to the extracellular media (Figure 6C). This is fully consistent as CelTOS does not bind phospholipids found predominantly in the outer leaflet of plasma membranes, rendering it incapable of disrupting plasma membranes from the extracellular face (Figure 3, Figure 6C and Figure 4—figure supplement 1C).

A model for CelTOS during cell traversal

This study provides unprecedented insight into the structure, function and mechanism of a critical protein involved in host and vector cell traversal by apicomplexan parasites. We have identified CelTOS as the only parasite protein known to breach plasma membranes from the cytoplasmic face to enable the exit of parasites from cells during traversal. The data from this study support the model depicted in Figure 7. CelTOS is released from parasite secretory organelles and adheres to the surface of the malaria parasite prior to and during the traversal of host and vector cells (Bergmann-
Leitner et al., 2010, 2011). Our results show that when the parasite is extracellular, CelTOS has limited cell membrane disrupting activity due to its low preference for lipids on the outer surface of plasma membranes. Once the parasite invades the cytosol of host and vector cells, CelTOS binds with high specificity to lipids in the inner leaflet of the plasma membrane. Binding leads to localized membrane disruption and pore formation that creates a portal to ultimately direct the exit of the parasite from the host or vector cells to complete traversal.

Discussion

Traversal of apicomplexan parasites across cells of their arthropod vectors and vertebrate hosts is required for transmission and disease progression (Homer et al., 2000; Shaw, 2003; Mota et al., 2001; Yuda and Ishino, 2004; Amino et al., 2008; Sinnis and Zavala, 2012). Parasites utilize gliding motility during traversal and have the ability to breach plasma membranes from the extracellular space to invade cells. Parasite proteins involved in gliding motility (Yuda and Ishino, 2004; Tardieux and Ménard, 2008), and the breaching of plasma membranes from the extracellular space to enable entry (Kadota et al., 2004; Risco-Castillo et al., 2015; Ishino et al., 2005) have been reported. The current literature supports a model where perforin-like proteins (PLPs) mediate entry into various pre-erythrocytic cells including the PLP-1 dependent disruption of transient vacuoles created during entry of hepatocytes (Risco-Castillo et al., 2015; Ishino et al., 2005). This suggests a mechanism in which PLPs engage outer leaflet lipids for disruption, although direct studies probing
the biochemical function and lipid specificity of PLPs have not been described. Further, PLPs have been shown to play a role in egress of parasites from the parasitophorous vacuole and red blood cells (Garg et al., 2013; Wirth et al., 2014). However, proteins involved in breaching the plasma membrane of invaded cells during traversal, from the cytoplasmic face, to enable the exit of parasites are unknown.

We have discovered that secreted apicomplexan CelTOS attacks plasma membranes from the cytoplasmic face. CelTOS had previously been identified as a malaria antigen, and CelTOS-deficient parasites are unable to traverse cells of their host and vector (Kariu et al., 2006; Doolan et al., 2003). The results of our study indicate that CelTOS functions to breach plasma membranes from the cytoplasmic face to enable the exit of parasites from invaded cells during traversal. This study challenges the paradigm that motility alone is sufficient for parasite exit, as it is now clear that active membrane disruption by CelTOS is necessary for parasite release. This work identifies CelTOS-dependent pore formation leading to inner-leaflet membrane disruption as a new active molecular process during traversal, and presents novel avenues for preventing traversal by inhibiting inner leaflet membrane disruption. As CelTOS is conserved across several large groups of apicomplexan parasites including Plasmodium spp., Cytaxzoon, Theileria and Babesia, this finding informs fundamental pathogen biology applicable to multiple diseases and microorganisms of global importance with particular relevance to cell infection, traversal and membrane disruption.

While CelTOS resembles viral membrane fusion proteins and a bacterial pore-forming toxin, our findings define a new class of membrane disruption proteins. CelTOS has a distinct structural architecture with two subdomains that independently resemble membrane binding and/or disrupting proteins and could simultaneously act during disruption (Figure 2). Further, CelTOS employs a unique lipid specificity for phosphatidic acid to achieve nearly universal inner leaflet cellular activity. This new class is also supported by the fact that primary sequence similarity searches did not identify membrane disruption proteins as relatives of CelTOS.

Both the N-terminal and C-terminal helices in CelTOS resemble the heptad repeats that form helices in class I viral fusion proteins (Figure 2A–C) (Sackett and Shai, 2002; Harrison, 2015; LeDuc and Shin, 2000). Viral heptad repeats undergo conformational changes that enhance the destabilization of host membranes post-insertion of the viral fusion peptide that enables lipid mixing during fusion (38). It is plausible that the N- and C-terminal helices in CelTOS may also undergo similar conformational changes during membrane disruption. However, CelTOS employs a distinct membrane disruption mechanism from viral proteins as lipid mixing is not required for CelTOS to target inner leaflet lipids and disrupt plasma membranes.
In addition, CelTOS is structurally similar to the pore-forming toxin M. tuberculosis ESAT-6 (Figure 2D) (Hsu et al., 2003; Los et al., 2013; Smith et al., 2008). However, these toxins generally recognize a host cell target or receptor embedded within the target membrane, and ESAT-6 is secreted in complex with a chaperone that maintains it in an inactive state. Upon binding the membrane target, the toxin sheds the chaperone, oligomerizes and embeds into the membrane to form a pore on the angstrom length scale for the passage of ions and water (Los et al., 2013). In contrast to a membrane-embedded target or receptor, CelTOS specifically binds phosphatidic acid within the inner leaflet of host or vector cell membranes. The dimeric nature of CelTOS may serve as a chaperone-like function to retain CelTOS in an inactive state prior to membrane binding as the dimer masks the inner hydrophobic faces of CelTOS. We provide evidence from dextran block experiments and transmission electron microscopy that CelTOS forms a pore of uniform size in liposomes.

Malaria continues to be a global health problem, with half of the world’s population at risk. The lack of an effective vaccine against malaria, and the continuous evolution of drug-resistant parasites make malaria control difficult. Targeting the liver-stage (Good and Doolan, 1999) and mosquito-stages (mCGo, 2011) are of high priority for malaria vaccine development. Immunization of human volunteers with radiation-attenuated sporozoites induces sterile immunity (Good and Doolan, 1999; Hoffman et al., 2002), and all volunteers showed strong immune responses to CelTOS (referred to as Antigen 2) that were correlated with protection (Doolan et al., 2003). In contrast, circumsporozoite protein, which is the major component of the most advanced malaria vaccine RTS,S (Crompton et al., 2010), was only recognized by a third of the volunteers and mostly in those who were not protected (Doolan et al., 2003). Individuals living in malaria endemic regions mount IFN-γ responses to CelTOS suggesting that CelTOS is a target of protective immunity (Anum et al., 2015). CelTOS is also unique as it is a promising multi-stage malaria vaccine target (Bergmann-Leitner et al., 2010; Ferraro et al., 2013; Bergmann-Leitner et al., 2011, 2013) for both infection-blocking and transmission-blocking vaccines currently in clinical trials.

We show that CelTOS has conserved critical function in both Plasmodium falciparum and Plasmodium vivax that infect humans. The high-sequence similarity between Pf and PvCelTOS suggest that CelTOS may elicit cross-species protection. Therefore, CelTOS could be used alone or in combination with other antigens already in development to produce an effective multicomponent vaccine which targets both the mosquito and human stages and may be cross-species protective (Doolan et al., 2003; Crompton et al., 2010; Crosnier et al., 2011). CelTOS-based vaccines have demonstrated the ability to elicit protection from malaria infection. However, protection is not absolute suggesting improvements in the immunogenicity, protectivity and formulation of CelTOS-based vaccines are necessary. Structure-function studies not only provide mechanistic insight into host-pathogen interactions (Tolia et al., 2005; Batchelor et al., 2011; Vulliez-Le Normand et al., 2012; Doud et al., 2012; Malpede et al., 2013; Batchelor et al., 2014; Wright et al., 2014; Lin et al., 2012), but also provide the necessary framework for improved vaccine design through structural vaccinology (Dormitzer et al., 2012; Chen et al., 2013, 2015, 2016). Immune recognition depends on antigen conformation and on surface accessibility of individual residues. The structure and architecture of CelTOS provides necessary insight to inform immune recognition, and enables protein engineering to retain the structural fold during immunogen design. The functional and mechanistic analyses presented here will enable assaying of immune responses for their ability to disrupt CelTOS function and provide an accurate molecular correlate for protection. Collectively, this work enables rational approaches to block CelTOS function, and rational approaches for vaccine development of global and emerging infectious diseases.

Materials and methods

Alignment of CelTOS from diverse apicomplexan parasites

CelTOS homologs in diverse apicomplexan parasites were identified using jackhammer and examination of the EuPathDB, and aligned in ClustalW.
Protein expression and purification
Codon-optimized PfCelTOS amino acids 25–182, PvCelTOS amino acids 36–196 and EclspF amino acids 1–159 with C-terminal hexahistidine tags, were expressed in E. coli. Tagged proteins were purified by Nickel-NTA chromatography and gel filtration using a Superdex 200 10/300 GL column (GE Healthcare Life Sciences, Pittsburg, PA).

Crystallization, data collection and structural studies
PvCelTOS crystals were grown at 17°C by hanging-drop vapor diffusion after mixing 1 μl of protein at 20 mg/ml with 1 μl of reservoir containing 1.6 M Ammonium dihydrogen phosphate, 0.08 M Tris pH 8.5 and 20% glycerol and streak seeding PvCelTOS crystals previously obtained from the same crystallization condition. Native PvCelTOS crystals were harvested and soaked for ~1 min in cryo-protectant solution containing: 1.6 M Ammonium dihydrogen phosphate, 0.08 M Tris pH 8.5 and 30% glycerol. Crystals of the PvCelTOS Platinum- derivative were obtained by soaking native CelTOS crystals for 1–2 min in cryo-protectant solutions containing: 10 μM Potassium tetracyanoplatinate hydrate, 1.6 M Ammonium dihydrogen phosphate, 0.08 M Tris pH 8.5 and 30% glycerol. Crystals of the CelTOS Mercury- derivative were obtained by soaking native CelTOS crystals for 1–2 min in cryo-protectant solutions containing: 1 μM mercury ethylphosphate, 1.6 M Ammonium dihydrogen phosphate, 0.08 M Tris pH 8.5 and 30% glycerol. The structure was phased in SHARP/ autoSHARP as multiple isomorphous replacement with anomalous scattering. Phases were extended by solvent flattening in SHARP/autoSHARP. The structure was refined in PHENIX with NCS restraints. Map and model manipulation was aided by the CCP4 program suite places this structure in the top 100th percentile of structures with comparable resolution. 98.44% and 1.56% of residues lie in the favored and allowed regions of the Ramachandran plot, respectively. Structurally similar PDBs were identified using the Dali server, and alignments and the normalized rmsd values obtained using Isqman. Buried surface area of the dimer was determined using PDB-PISA. Atomic coordinates and structure factors for the reported crystal structure were deposited into the Protein Data Bank under PDB code 5TSZ.

Analytical ultracentrifugation
Sedimentation equilibrium experiments were conducted with a Beckman/Coulter XL-A analytical ultracentrifuge (Beckman/Coulter, Indianapolis, IN) using an An60Ti rotor at 10°C and λ 286 nm. PfCelTOS and PvCelTOS were purified by gel filtration using a Superdex 200 10/300 GL column in 150 mM NaCl and 10 mM HEPES pH 7.4. Data were collected for speeds 12,000 rpm and 15,000 rpm with PfCelTOS at 25 μM, 36 μM and 46 μM, and PvCelTOS at 29 μM, 41 μM and 53 μM. A partial specific volume of 0.730919 and 0.737102 was calculated using Sednterp for PfCelTOS and PvCelTOS, respectively. Data were analyzed using a single component model with UltraScan II version 9.9. Average molecular weight is reported as mean ± s.d.

Membrane lipid screen
Membrane lipid strips (Echelon Biosciences Inc., Salt Lake City, UT) were probed with proteins according to the manufacturer specified protocol. Membrane strips were blocked at room temperature for 1 hr in blocking buffer (10 mM Tris pH 8.0, 150 mM NaCl, 0.1% Tween 20% and 3% BSA) and washed three times for 5 min with wash buffer (10 mM Tris pH 8.0, 150 mM NaCl and 0.1% Tween 20). PfCelTOS and PvCelTOS were incubated in blocking buffer at a concentration of 20 μM. Mouse anti-His monoclonal antibody (Invitrogen, Waltham, MA) diluted 1:500 in blocking buffer was used as the primary antibody, and Peroxidase AffiniPure Goat Anti-Mouse IgG (Jackson Laboratories) diluted 1:10,000 in blocking buffer as the secondary antibody. Binding was detected with ECL Prime Western Blotting Detection Kit (GE Healthcare Biosciences), imaged using Image Reader FLA-5000 series phosphorimager (Fuji PhotoFilm, Japan) and quantified using Image Gauge version 4.23 (Fuji PhotoFilm). Experiments were performed with eight replicates, along with one negative control where CelTOS was omitted. Spot intensities were normalized to background and the negative control strip. Data were analyzed by one-way ANOVA with Dunnett’s multiple comparison tests to compare the intensity of each lipid spot to the negative control on that strip using Prism 6.
software, La Jolla, CA). The normalized binding intensity of each spot was plotted as mean ± s.e.m. The membrane lipid screen is described in more detail at Bio-protocol (Jimah et al., 2017a).

**Liposome preparation and liposome disruption assay**

Liposomes used for experiments were composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho line (POPC) alone or in combination with either 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (POPA) or 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS) (Avanti Polar Lipids, Alabaster, AL). Chloroform-dissolved lipids were dried under N₂ gas followed by vacuum for 3 hr. To hydrate the lipids, equal volumes of ether and a solution composed of 10 mM HEPES pH 7.4, 150 mM KCl and 20 mM carboxyfluorescein were added to the lipids, the mixture sonicated and ether evaporated using a roto-vap. Liposomes were sized by extrusion using 200 nm polycarbonate Track-Etched filters (Whatman/Nucleopore). Size exclusion chromatography with Sephadex G 25–300 (Sigma Aldrich, Saint Louis, MO) was used to separate unincorporated carboxyfluorescein from liposomes. In all experiments, varying concentrations of proteins were incubated with liposomes containing 250 nM of lipids, and the time-dependence of liposome disruption was monitored using a Cary Eclipse Fluorescence Spectrophotometer (Varian Inc/ Agilent, Santa Clara CA) by observing the carboxyfluorescein fluorescence emission at 512 nm upon excitation at 492. Three replicate measurements were performed for each protein. The percent liposome disruption was calculated as:

\[
\text{%Disruption}_{\text{time}} = \left( \frac{F_{512\text{of liposome}+\text{protein}} - F_{512\text{of liposome}}}{F_{512\text{of liposome}+\text{triton}} - F_{512\text{of liposome}}} \right) \times 100
\]  

(1)

where 0.2% Triton X-100 was added to normalize each sample to complete dequenching as previously described, and data fitted to Equation 1 (Saito et al., 2000).

For kinetic and pore-forming analyses, the time dependence of liposome disruption was also fitted to the following Equation 2 (Saito et al., 2000):

\[
\text{%Liposomes Disrupted} = A(1 - e^{-\left(\frac{\text{time}}{\tau}\right)}) + m \times \text{time}
\]

(2)

where A is the maximum percentage of liposomes disrupted, Tau is the time constant for the exponential component, and m is the slope of the linear component.

For the liposome disruption assays with dextran, 20 μM dextran was added to liposomes, and then 250 nM of PICelTOS or PvCelTOS was added, and liposome disruption monitored. The maximum amount of liposome disrupted, A, was obtained by fitting the data to Equation 2. Data was analyzed using Prism 6 (GraphPad Software, La Jolla, CA) by performing a one-way ANOVA with Dunnett’s multiple comparison test. Data with seven experimental replicates of each preparation included as mean ± s.e.m. The membrane lipid screen is described in more detail at Bio-protocol (Jimah et al., 2017b).

**Microinjection of Xenopus laevis oocytes with Plasmodium CelTOS**

Mature female Xenopus laevis frogs were purchased from Xenopus Express (Brooksville, FL). All animal protocols followed guidelines approved by the Washington University School of Medicine and the National Institutes of Health. Frogs were anesthetized with a 0.1% tricaine solution buffered with 0.1% NaHCO₃ prior to survival surgery in which a portion of the ovary is removed. Stage V–VI oocytes were isolated and maintained at 18 in modified Barth’s solution of the following composition: 88 mM NaCl, 2.4 NaHCO₃, 1 mM KCl, 0.3 mM Ca(NO₃)₂, 0.4 mM CaCl₂, 0.8 mM MgSO₄ and 10 mM HEPES/Tris pH 7.4, and supplemented with 50 mg/l gentamicin, 6 mg/l ciprofloxacin, and 100 mg/l streptomycin sulfate/100,000 units/l penicillin G sodium (Life Technologies, Carlsbad, CA). One day after isolation, oocytes were microinjected with 50 nl (0.1 nmol, approximately 100 μM final concentration) of EclspF, PICelTOS or PvCelTOS, prepared fresh as 2 mM stock solutions in Protein buffer composed of 10 mM HEPES pH 7.4 and 150 mM KCl; non-injected oocytes, oocytes injected with 50 nl of protein buffer, and oocytes injected with EclspF, served as controls. Twenty-four oocytes per condition were individualized in 96-well plates, and monitored for membrane damage. Oocytes were monitored 24 hr post-infection under an Olympus SZX10 microscope (Olympus Corporation, Waltham, MA), and images captured with Infinity Lite camera using Infinity capture version 6.00 software (Lumnera Corporation). Results are shown as mean ± s.e.m. of six separate experiments with independent protein preparations and with oocytes from different donor frogs. Data
were analyzed using Prism 6 (GraphPad Software, La Jolla, CA) by performing Kruskal-Wallis followed by Dunn's multiple comparison tests.

**RAW 264.7 macrophage cytotoxicity assay**

RAW 264.7 cells (ATCC) liberated using CellStripper reagent (Corning, Corning, NY) were filtered through a 40 μm mesh to yield a single-cell suspension. Cells were seeded onto clear-bottomed, white-walled 96-well plates (Corning 3610) at 2 × 10⁵ cells per well in DMEM 10% FBS and allowed to adhere overnight. Wells were washed with PBS and assay reagents added. The assay was conducted in 5% FBS with phenol-red-free DMEM. Recombinant proteins were added to 100 μM final concentration. Triton X-100 at a final concentration of 0.05% v/v served as a positive control. Total reaction volume was 100 μl. The plates were incubated at 37°C, 5% CO₂ for 3.5 hr prior to the addition of 50 μl 1x CellTox Green reagent (Promega, Madison, WI) and incubated for a further 30 min. Fluorescence at 485 nm was read using a Cytation 3 Cell Imaging Multimode Reader (Biotek, Winooski, VT). Results are shown as the mean ± s.e.m. of three separate experiments with independent RAW 264.7 cells each with three technical replicates. Data were analyzed using Prism 6 (GraphPad Software, La Jolla, CA) by performing Kruskal-Wallis and Dunn's multiple comparison tests.

**Transmission electron microscopy**

Liposomes were treated with either 250 μM PfCelTOS or PvCelTOS. Suspension of liposomes were then allowed to absorb onto freshly glow discharged formvar/carbon-coated copper grids for 10 min. Grids were washed in dH₂O and stained with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for 1 min. Excess liquid was gently wicked off and grids were allowed to air dry. Samples were viewed on a JEOL 1200EX transmission electron microscope (JEOL USA, Peabody, MA) equipped with an AMT megapixel digital camera (Advanced Microscopy Techniques, Woburn, MA). Pore diameters were determined using ImageJ 1.48V.

**Acknowledgements**

This work was supported by the National Institutes of Health (R56 AI080792 to NHT) and the Burroughs Wellcome Fund (to NHT). We thank J Nix and ALS Beamline 4.2.2 supported by contract DE-AC02-05CH11231. We thank W Beatty and B Anthony of the Molecular Microbiology Imaging Facility, School of Medicine, Washington University in St Louis. The authors declare there are no conflicts of interest.

**Additional information**

| Funding | Grant reference number | Author |
|---------|------------------------|--------|
| Burroughs Wellcome Fund | R56 AI080792 | Niraj H Tolia |
| National Institutes of Health | R56 AI080792 | Niraj H Tolia |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**Author contributions**

J RJ, MS-R, NHT, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article; NDS, NGJ, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article; LDS, CGN, Analysis and interpretation of data, Drafting or revising the article; PHS, Conception and design, Analysis and interpretation of data, Drafting or revising the article

**Author ORCID(s)**

Niraj H Tolia, [http://orcid.org/0000-0002-2689-1337](http://orcid.org/0000-0002-2689-1337)
Animal experimentation: All procedures followed guidelines approved by the Washington University School of Medicine and the National Institutes of Health, as outlined in Washington University Animal Studies Committee protocol number 2015-0110.

References
Adams PD, Grosse-Kunstleve RW, Hung LW, Loerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC. 2002. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallographica Section D Biological Crystallography 58:1948–1954. doi: 10.1107/S090744490216657, PMID: 12393927

Amino R, Giovannini D, Thibierge S, Guierard P, Boisson B, Dubremetz JF, Prévost MC, Ishino T, Yuda M, Ménard R. 2008. Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. *Cell Host & Microbe* 3:88–96. doi: 10.1016/j.chom.2007.12.007, PMID: 18312843

Anum D, Kusi KA, Ganeshan H, Hollingdale MR, Ofori MF, Koram KA, Gyan BA, Adu-Amankwah S, Badji E, Huang J, Belmonte M, Banania GJ, Kwofie TB, Villasante E, Dodoo D, Sedeagh M. 2015. Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinete and sporozoite (CeToTs) in Ghanaian adults. *Malaria Journal* 14:20. doi: 10.1186/s12936-014-0539-5, PMID: 25604473

Armstrong JK, Wenby RB, Meiselman HJ, Fisher TC. 2004. The hydrodynamic radii of macromolecules and their effect on red blood cell aggregation. *Biophysical Journal* 87:4259–4270. doi: 10.1529/biophysj.104.047746, PMID: 15361408

Batchelor JD, Malpede BM, Ommatage NS, DeKoster GT, Henschler-Wildman KA, Tolia NH. 2014. Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC. *PLoS Pathogens* 10:e1003869. doi: 10.1371/journal.ppat.1003869, PMID: 24415938

Batchelor JD, Zahm JA, Tolia NH. 2011. Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC. *Nature Structural & Molecular Biology* 18:908–914. doi: 10.1038/nsmb.2088, PMID: 21743458

Bergmann-Leitner ES, Hosie H, Trichilo J, Deriso E, Ranallo RT, Alefantis T, Savranskaya T, Grewal P, Ockenhouse CF, Venkatesan MM, Delvecchio VG, Angov E. 2013. Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens mediating sterile protection against malaria. *Frontiers in Immunology* 4:176. doi: 10.3389/fimmu.2013.00176, PMID: 23847617

Bergmann-Leitner ES, Legler PM, Savranskaya T, Ockenhouse CF, Angov E. 2011. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CeToTs. *Vaccine* 29:5940–5949. doi: 10.1016/j.vaccine.2011.06.053, PMID: 21722682

Bergmann-Leitner ES, Meese RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, Angov E. 2010. Immunization with pre-erythrocytic antigen CeToTs from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. *PLoS One* 5:e12294. doi: 10.1371/journal.pone.0012294, PMID: 20808688

Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, Eisele T, Liu L, Mathers C, Child Health Epidemiology Reference Group of WHO and UNICEF. 2010. Global, regional, and national causes of child mortality in 2008: a systematic analysis. The Lancet 375:1969–1987.

Buzon V, Natrajgan G, Schibi D, Campbell F, Kozlov MM, Weissenhorn W. 2010. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. *PLoS Pathogens* 6:e1000880. doi: 10.1371/journal.ppat.1000880, PMID: 20463810

Chen E, Paing MM, Salinas N, Sim BK, Tolia NH. 2013. Structural and functional basis for inhibition of erythrocyte invasion by antibodies that target Plasmodium falciparum EBA-175. *PLoS Pathogens* 9:e1003390. doi: 10.1371/journal.ppat.1003390, PMID: 23717209

Chen E, Salinas ND, Huang Y, Ntumngia F, Plasencia MD, Gross ML, Adams JH, Tolia NH. 2016. Broadly neutralizing epitopes in the *Plasmodium vivax* vaccine candidate Duffy Binding Protein. *PNAS* 113:6277–6282. doi: 10.1073/pnas.1600488113

Chen E, Salinas ND, Ntumngia FB, Adams JH, Tolia NH. 2015. Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine development. *PLoS Neglected Tropical Diseases* 9:e0003644. doi: 10.1371/journal.pntd.0003644, PMID: 25793371

Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. *Acta Crystallographica. Section D, Biological Crystallography* 50:760. doi: 10.1107/S0907444994003112, PMID: 15293974

Crompton PD, Pierce SK, Miller LH. 2010. Advances and challenges in malaria vaccine development. *Journal of Clinical Investigation* 120:4168–4178. doi: 10.1172/JCI44423, PMID: 21123952

Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, Uchikawa M, Mboup S, Ndir O, Kwiatkowski DP, Duraisingh MT, Rayner JC, Wright GJ. 2011. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. *Nature* 480:534–537. doi: 10.1038/nature10660, PMID: 22080952

Davis IW, Leaver-Fay A, Chen VB, Block JS, Kapral GJ, Wang X, Murray LW, Arendall WB, Snoeyink J, Richardson JS, Richardson DC. 2007. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Research* 35:W375–W383. doi: 10.1093/nar/gkm216, PMID: 17452350
DeBarry JD, Kissinger JC. 2011. Jumbled genomes: missing Apicomplexan synteny. *Molecular Biology and Evolution* **28**:2855–2871. doi: 10.1093/molbev/msr103, PMID: 21504890

Doolan DL, Southwood S, Frelich DA, Sidney J, Graber NL, Shatney L, Bebris L, Floresn L, Dobano C, Witney AA, Appella E, Hoffman SL, Yates JR, Carucci DJ, Sette A. 2003. Identification of *Plasmodium falciparum* antigens by antigenic analysis of genomic and proteomic data. *PNAS* **100**:9952–9957. doi: 10.1073/pnas.1632254100

Dormitzer PR, Grandi G, Rappuoli R. 2012. Structural vaccinology starts to deliver. *Nature Reviews Microbiology* **10**:807–813. doi: 10.1038/nrmicro2893, PMID: 23154420

Doudb MB, Koksal AC, Mi LZ, Song G, Lu C, Springer TA. 2012. Unexpected fold in the circumsporozoite protein target of malaria vaccines. *PNAS* **109**:7817–7822. doi: 10.1073/pnas.1205737109

Ferraro B, Talbott KT, Balakrishnan A, Cisper N, Morrow MP, Hutnick NA, Myles DJ, Shedlock DJ, Obeng-Adjei N, Yan J, Kayatani AK, Richie N, Cabrera W, Shiver R, Khan AS, Brown AS, Yang M, Wille-Reece U, Birkett AJ, Sardesai NY, et al. 2013. Humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. *Infection and Immunity* **81**:3709–3720. doi: 10.1128/IAI.00180-13, PMID: 23897618

Garg S, Agarwal S, Kumar S, Yazdani SS, Chitnis CE, Singh S, Shams Yazdani S. 2013. Calcium-dependent permeabilization of erythrocytes by a perforin-like protein during egress of malaria parasites. *Nature Communications* **4**:1736. doi: 10.1038/ncomms2725, PMID: 23591903

Good MF, Doolan DL. 1999. Immune effector mechanisms in malaria. *Current Opinion in Immunology* **11**:412–419. doi: 10.1016/S0952-7915(99)80069-7, PMID: 10448141

Guiérrard P, Tavares J, Thibierge S, Bernex F, Ishino T, Milon G, Franke-Fayard B, Janse CJ, Menard R, Amino R. 2010. Development of the malaria parasite in the skin of the mammalian host. *PNAS* **107**:18640–18645. doi: 10.1073/pnas.1009346107

Harrison SC. 2015. Viral membrane fusion. *Virology* **479-480**:498–507. doi: 10.1016/j.virol.2015.03.043, PMID: 25863737

Harupa A, Sack BK, Lakshmanan V, Arang N, Douglass AN, Oliver BG, Stuart AB, Sather DN, Lindner SE, Hybiske K, Torii M, Kappe SH. 2014. SSP3 is a novel *Plasmodium yoelii* sporozoite surface protein with a role in gliding motility. *Infection and Immunity* **82**:4643–4653. doi: 10.1128/IAI.01800-14, PMID: 25156733

Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL. 2002. Protection of humans against malaria by immunization with radiation-attenuated *Plasmodium falciparum* sporozoites. *The Journal of Infectious Diseases* **185**:1155–1164. doi: 10.1086/339409, PMID: 11903362

Holm L, Rosenstrom P, server D. 2010. Dali server: conservation mapping in 3D. *Nucleic Acids Research* **38**:W545–W549. doi: 10.1093/nar/gkq366

Homer MJ, Aguilar-Delfin I, Telford SR, Krause PJ, Persing DH. 2000. Babesiosis. *Clinical Microbiology Reviews* **13**:451–469. doi: 10.1128/CMR.13.3.451-469.2000, PMID: 10885987

Hsu T, Hingley-Wilson SM, Chen B, Chen M, Dai AZ, Morin PM, Marks CB, Padiyar J, Goulding C, Gingery M, Eisenberg D, Russell RG, Derrick SC, Collins FM, Morris SL, King CH, Jacobs WR. 2003. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. *PNAS* **100**:12420–12425. doi: 10.1073/pnas.1635213100

Ishino T, Chizey Y, Yuda M. 2005. A *Plasmodium* sporozoite protein with a membrane attack complex domain is required for breaching the liver sinusoidal cell layer prior to hepatocyte infection. *Cellular Microbiology* **7**:199–208. doi: 10.1111/j.1462-5822.2004.00447.x, PMID: 15659064

Jimah JR, Schlesinger PH, Tolia NH. 2017a. Membrane Lipid Screen to Identify Molecular Targets of Biomolecules. *BIO-PROTOCOL* **7**:e2427. doi: 10.21769/BioProtoc.2427

Jimah JR, Schlesinger PH, Tolia NH. 2017b. Liposome Disruption Assay to Examine Lytic Properties of Biomolecules. *BIO-PROTOCOL* **7**:e2433. doi: 10.21769/BioProtoc.2433

Kadota K, Ishino T, Matsuyama T, Chizey Y, Yuda M. 2004. Essential role of membrane-attack protein in malarial transmission to mosquito host. *PNAS* **101**:16310–16315. doi: 10.1073/pnas.0406187101, PMID: 15520375

Kariu T, Ishino T, Yano K, Chizey Y, Yuda M. 2006. CellTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. *Molecular Microbiology* **59**:1369–1379. doi: 10.1111/j.1365-2958.2005.05024.x, PMID: 16468985

Kleywegt GJ. 1996. Use of non-crystallographic symmetry in protein structure refinement. Acta Crystallographica Section D Biological Crystallography **52**:842–857. doi: 10.1107/S0907444995016477, PMID: 15299650

Krisinel E, Henrick K. 2007. Inference of macromolecular assemblies from crystalline state. *Journal of Molecular Biology* **372**:774–797. doi: 10.1016/j.jmb.2007.05.022, PMID: 17681537

LeDuc DL, Shin YK. 2000. Insights into a structure-based mechanism of viral membrane fusion. *Bioscience Reports* **20**:557–570. doi: 10.1023/A:1010463005396, PMID: 11426694

Lin DH, Malpede BM, Batchelor JD, Tolia NH. 2012. Crystal and solution structures of *Plasmodium falciparum* erythrocyte-binding antigen 140 reveal determinants of receptor specificity during erythrocyte invasion. *Journal of Biological Chemistry* **287**:36830–36836. doi: 10.1074/jbc.M112.409276, PMID: 22989878

Los FC, Randis TM, Aroian RV, Ratner AJ. 2013. Role of pore-forming toxins in bacterial infectious diseases. *Microbiology and Molecular Biology Reviews* **77**:173–207. doi: 10.1128/MMBR.00252-12, PMID: 23699254

Lou Z, Xu Y, Xiang K, Su N, Qin L, Li X, Gao GF, Bartlam M, Rao Z, Li X GGF. 2006. Crystal structures of Nipah and Hendra virus fusion core proteins. *FEBS Journal* **273**:4538–4547. doi: 10.1111/j.1742-4658.2006.05459.x, PMID: 16972940
malERA Consultative Group on Vaccines. 2011. A research agenda for malaria eradication: vaccines. *PLoS Medicine* **8**:e1000398. doi: 10.1371/journal.pmed.1000398

Malpede BM, Lin DH, Tolia NH. 2013. Molecular basis for sialic acid-dependent receptor recognition by the Plasmodium falciparum invasion protein erythrocyte-binding antigen-140/BAEBL. *Journal of Biological Chemistry* **288**:12406–12415. doi: 10.1074/jbc.M113.450643, PMID: 23508963

Ménard R, Tavares J, Cockburn I, Markus M, Zavala F, Amino R. 2013. Looking under the skin: the first steps in malarial infection and immunity. *Nature Reviews Microbiology* **11**:701–712. doi: 10.1038/nrmicro3111, PMID: 24037451

Moreira CK, Templeton TJ, Lavazec C, Hayward RE, Hobbs CV, Kroeeze H, Janse CJ, Waters AP, Sinnis P, Coppi A. 2008. The Plasmodium falciparum TRAP/MIC2 family member, TRAP-Like Protein (TLP), is involved in tissue traversal by sporozoites. *Cellular Microbiology* **10**:1505–1516. doi: 10.1111/j.1462-5822.2008.00772.x, PMID: 18346224

Mota MM, Pradel G, Vanderberg JP, Hafalla JC, Frevert U, Nussenzweig RS, Nussenzveig V, Rodrı́guez A. 2001. Migration of Plasmodium sporozoites through cells before infection. *Science* **291**:141–146. doi: 10.1126/science.291.5501.141, PMID: 11141568

Op den Kamp JA. 1979. Lipid asymmetry in membranes. *Annual Review of Biochemistry* **48**:47–71. doi: 10.1146/annurev.bi.48.070179.000403, PMID: 382989

Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. 2007. Vivax malaria: neglected and not benign. *The American Journal of Tropical Medicine and Hygiene* **77**:79–87. PMID: 18165478

Renshaw PS, Lightbody KL, Veverka V, Musckett FW, Kelly G, Frenkiel TA, Gordon SV, Hewinson RG, Burke B, Norman J, Williamson RA, Carr MD. 2005. Structure and function of the complex formed by the tuberculosis virulence factors CFP-10 and ESAT-6. The *EMBO Journal* **24**:2491–2498. doi: 10.1038/sj.emboj.7600752, PMID: 15973432

Risco-Castillo V, Topçu S, Marinach C, Manzoni G, Bigorgne AE, Briquet S, Baudin X, Lebrun M, Dubremetz JF, Silvie O. 2015. Malaria sporozoites traverse host cells within transient vacuoles. *Cell Host & Microbe* **18**:593–603. doi: 10.1016/j.chom.2015.10.006, PMID: 26607162

Sackett K, Shai Y. 2002. The HIV-1 gp41 N-terminal heptad repeat plays an essential role in membrane fusion. *Biochimie* **84**:4678–4685. doi: 10.1016/i.biochi.2002.05.004, PMID: 11926830

Saito M, Korsmeyer SJ, Schlesinger PH. 2000. BAX-dependent transport of cytochrome c reconstituted in pure liposomes. *Nature Cell Biology* **2**:553–555. doi: 10.1038/35019596, PMID: 10934477

Shaw MK. 2003. Cell invasion by Theliera sporozoites. *Trends in Parasitology* **19**:2–6. doi: 10.1016/S1471-4922(02)00015-6, PMID: 12488213

Sherrill MK, Cohn LA, Cytaxozoonosis CLA. 2015. Cytaxozoonosis: Diagnosis and treatment of an emerging disease. *Journal of Feline Medicine and Surgery* **17**:940–948. doi: 10.1177/1098615X15610681, PMID: 26486980

Sinnis P, Zavala F. 2012. The skin: where malaria infection and the host immune response begin. *Seminars in Immunopathology* **34**:787–792. doi: 10.1007/s00281-012-0345-5, PMID: 23053392

Smith J, Manoranjan J, Pan M, Bohsali A, Xu J, Liu J, McDonald KL, Szyk A, LaRonde-LeBlanc N, Gao LY. 2008. Evidence for pore formation in host cell membranes by ESX-1-secreted ESAT-6 and its role in Mycobacterium marinum escape from the vacuole. *Infection and Immunity* **76**:5478–5487. doi: 10.1128/IAI.00614-08, PMID: 18852239

Tang Y, Ito K, Hong L, Ishizone T, Yokoyama H. 2016. Tunable thermoresponse mesoporous block copolymer membranes. *Macromolecules* **49**:7886–7896. doi: 10.1021/acs.macromol.6b01665

Tardieux I, Ménard R. 2008. Migration of Apicomplexa across biological barriers: the Toxoplasma and Plasmodium rida. *Traffic* **9**:627–635. doi: 10.1111/j.1600-0854.2008.00703.x, PMID: 18194412

Tolia NH, Enemark EJ, Sim BK, Joshua-Tor L. 2005. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. *Cell* **122**:183–193. doi: 10.1016/j.cell.2005.05.033, PMID: 16051144

Vonrhein C, Blanc E, Roversi P, Bricogne G. 2007. Automated structure solution with autoSHARP. *Methods in Molecular Biology* **364**:215–230. doi: 10.1385/1-59745-266-1:215, PMID: 17172768

Wirth CC, Glushakova S, Scheuemayer M, Repnik U, Garg S, Schaack D, Kachman MM, Weißbach T, Zimmerberg J, Dandekar T, Griffiths G, Chitnis CE, Singh S, Fischer R, Pradel G. 2014. Perforin-like protein PPLP2 permeabilizes the red blood cell membrane during egress of *Plasmodium falciparum* gametocytes. *Biological Microbiology* **16**:709–733. doi: 10.1111/cmi.12288, PMID: 24602217

Wright KE, Hjerrild KA, Bricogne G, Jermiin LS, Didier S, Duval C, Dill J, Brown RE, Illingworth JJ, Ashfield R, Clemenсен SB, de Jongh WA, Draper SJ, Higgins MK. 2014. Structure of malaria invasion protein RSH with erythrocyte basigin and blocking antibodies. *Nature* **515**:427–430. doi: 10.1038/nature13715, PMID: 25132548

Yuda M, Ishino T. 2004. Liver invasion by malarial parasites—how do malarial parasites break through the host barrier? *Cellular Microbiology* **6**:1119–1125. doi: 10.1111/j.1462-5822.2004.00474.x, PMID: 15527492

Zheng H, Tan Z, Xu W. 2014. Immune evasion strategies of pre-erythrocytic malaria parasites. *Mediators of Inflammation* **2014**:1–6. doi: 10.1155/2014/362605